SAB Biotherapeutics (SABS) Free Cash Flow (2020 - 2026)
SAB Biotherapeutics (SABS) posted Free Cash Flow of -$14.5 million for Q1 2026, up 13.41% on a QoQ basis from -$16.8 million in Q4 2025, and down 86.3% year-over-year from -$106.1 million in Q1 2025.
SAB Biotherapeutics (SABS) Free Cash Flow (2020 - 2026) Analysis & Trends
SAB Biotherapeutics' Free Cash Flow history runs 7 years deep, the most recent figure standing at -$14.5 million for Q1 2026.
- Quarterly Free Cash Flow fell 86.3% year-over-year to -$14.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$51.5 million (down 63.26% YoY) and the FY2025 annual result came in at -$45.7 million, down 31.99% from the prior year.
- Free Cash Flow was -$14.5 million for Q1 2026 at SAB Biotherapeutics, up from -$16.8 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$1.6 million in Q1 2023 and bottomed at -$16.8 million in Q4 2025.
- A 5-year average of -$8.5 million and a median of -$7.8 million in 2025 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2022 — Free Cash Flow slumped 1504.71% — and 2023, when it soared 85.07%.
- SAB Biotherapeutics' Free Cash Flow stood at -$1.7 million in 2022, then plunged by 707.91% to -$13.5 million in 2023, then advanced by 29.06% to -$9.6 million in 2024, then sank by 74.98% to -$16.8 million in 2025, then rose by 13.41% to -$14.5 million in 2026.
- Business Quant data shows SABS's Free Cash Flow at -$14.5 million in Q1 2026, -$16.8 million in Q4 2025, and -$13.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 158.09 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.95 Mn |
| 10 | SAB Biotherapeutics | 170.64 Mn | 170.64 Mn | - | -14.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.53 Mn |
| Mar 31, 2026 | -14.53 Mn |
| Dec 31, 2025 | -16.78 Mn |
| Dec 31, 2025 | -16.78 Mn |
| Sep 30, 2025 | -13.05 Mn |
| Sep 30, 2025 | -13.05 Mn |
| Jun 30, 2025 | -7.15 Mn |
| Jun 30, 2025 | -7.15 Mn |
| Mar 31, 2025 | -7.80 Mn |
| Mar 31, 2025 | -7.80 Mn |
| Dec 31, 2024 | -9.59 Mn |
| Dec 31, 2024 | -9.59 Mn |
| Sep 30, 2024 | -6.39 Mn |
| Sep 30, 2024 | -6.39 Mn |
| Jun 30, 2024 | -7.77 Mn |
| Jun 30, 2024 | -7.77 Mn |
| Mar 31, 2024 | -10.88 Mn |
| Mar 31, 2024 | -10.88 Mn |
| Dec 31, 2023 | -13.51 Mn |
| Dec 31, 2023 | -13.51 Mn |